Valeant Counters Allergan R&D Claims As Hostile Play Looms
Under scrutiny for recent cuts to its research and development operations, Valeant Pharmaceuticals International Inc. on Wednesday circulated a presentation defending its approach to innovation as it bears down on a...To view the full article, register now.
Already a subscriber? Click here to view full article